Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptoms

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOvationLab

About this trial

A single-arm, open-label prospective study will be conducted evaluating the impact of 8 weeks of supplementation at the manufacturer-recommended dose of Complete Commensal Probiotic™ on the GI-MAP stool test panel (Diagnostic Solutions Laboratory, Alpharetta, GA), gastrointestinal symptoms, digestion-associated quality of life. and overall physical health, mental health, and anxiety.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult females or males age ≥ 18 years

At least moderate gastrointestinal distress, defined as a score of ≥ 4 on any domain of the Gastrointestinal Symptoms Rating Scale (GSRS) at screening

Ability to read and speak English

Ability and willingness to collect an at-home stool sample for GI-MAP testing

Disqualifiers

Current or recent (within the prior 90 days) use of a probiotic dietary supplement

Current or recent (within the prior 90 days) use of systemic antibiotics, antifungals, or antiparasitic medications

Known allergies to any ingredients in the product

Currently pregnant or lactating women or women planning to become pregnant in the next 8 weeks

Trial design

Design model

Single group

Treatments tested in this trial

  • Complete Commensal Probiotic

    Dietary supplement

    Complete Commensal Probiotic™ contains five established commensal strains selected for their documented physiologic roles in the healthy adult gut. The five commensal strains in the product in this study are Akkermansia muciniphila (TA09), Bifidobacterium adolescentis (TA38), Bifidobacterium longum (TA24), Faecalibacterium prausnitzii (TA35), and Roseburia intestinalis (TA08).

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: Complete Commensal ProbioticExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Relative Abundance of Commensal Microorganisms

Counts of microbes per gram of each organism on GI-MAP test

Time frame
Baseline and end of 8-week intervention

Secondary outcomes

1

Functional and Microbial Markers of Intestinal Health

Functional and microbial markers of intestinal health on the GI-MAP will be categorized as low, medium, and high

Time frame
Baseline and end of 8-week intervention
2

Gastrointestinal Symptoms Rating Scale

Validated questionnaire assessing gastrointestinal symptoms. Total scores across all domains range from 15-105. Higher scores indicate worse gastrointestinal symptoms.

Time frame
Baseline and end of 8-week intervention
3

Digestion-Associated Quality of Life Questionnaire

Validated questionnaire assessing the impact of digestion on quality of life. Total scores across all domains range from 0 to 81. Higher scores indicate worse digestion-associated quality of life.

Time frame
Assessed at baseline and end of 8-week study.
4

PROMIS - Global Health

Validated questionnaire assessing global physical and mental health. T scores range from 16.2 to 67.7 for physical health and from 21.2 to 67.6 for mental health. Higher scores indicate better physical and mental health.

Time frame
Baseline and end of 8-week study.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: